Toi M, Osaki A, Yamada H, Toge T
Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, U.K.
Eur J Cancer. 1991;27(8):977-80. doi: 10.1016/0277-5379(91)90262-c.
The significance of epidermal growth factor receptor (EGFR) status as a prognostic indicator was investigated by a competitive binding assay in 135 primary breast cancer patients. 55 patients (41%) were EGFR positive and EGFR status was negatively correlated with oestrogen receptor (ER) status (P less than 0.01). 5-year postoperative follow-up showed that relapse-free survival for EGFR positive patients was significantly worse than that for EGFR negative patients (P less than 0.05). There was no difference between the two groups in tumour size, axillary node involvement, age and menopausal status. Analysis by axillary node status demonstrated the poor prognosis of the EGFR positive group in node positive patients. As yet, no difference in prognosis has been seen in node negative patients. A higher frequency of haematopoietic relapse was observed in EGFR positive patients. Simultaneous or sequential EGFR measurements in primary tumour and metastatic sites of 34 patients showed that expression of EGFR was more enhanced in metastatic sites.
通过竞争性结合试验对135例原发性乳腺癌患者的表皮生长因子受体（EGFR）状态作为预后指标的意义进行了研究。55例患者（41%）EGFR呈阳性，且EGFR状态与雌激素受体（ER）状态呈负相关（P<0.01）。术后5年随访显示，EGFR阳性患者的无复发生存期明显差于EGFR阴性患者（P<0.05）。两组在肿瘤大小、腋窝淋巴结受累情况、年龄和绝经状态方面无差异。按腋窝淋巴结状态分析表明，EGFR阳性组在淋巴结阳性患者中预后较差。目前，在淋巴结阴性患者中尚未观察到预后差异。在EGFR阳性患者中观察到更高频率的造血系统复发。对34例患者的原发性肿瘤和转移部位同时或序贯进行EGFR检测，结果显示EGFR在转移部位的表达增强更为明显。
